发明授权
US08039585B2 Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
有权
加扰的抗血管生成肽C16Y的治疗施用
- 专利标题： Therapeutic administration of the scrambled anti-angiogenic peptide C16Y
- 专利标题（中）： 加扰的抗血管生成肽C16Y的治疗施用
-
申请号： US10588884申请日： 2004-02-12
-
公开(公告)号： US08039585B2公开(公告)日： 2011-10-18
- 发明人: Karl G. Csaky , Hynda Kleinman , Lourdes Ponce
- 申请人： Karl G. Csaky , Hynda Kleinman , Lourdes Ponce
- 申请人地址： US DC Washington
- 专利权人： The United States of America as represented by the Department of Health and Human Services
- 当前专利权人： The United States of America as represented by the Department of Health and Human Services
- 当前专利权人地址： US DC Washington
- 代理机构： Woodcock Washburn LLP
- 国际申请： PCT/US2004/004142 WO 20040212
- 国际公布： WO2005/087250 WO 20050922
- 主分类号： A61K38/04
- IPC分类号： A61K38/04 ; A61K38/00 ; A61K51/00 ; A61P35/00 ; C07K5/00 ; C07K7/00 ; C07K16/00 ; C07K17/00
摘要：
Unregulated angiogenesis is associated with a variety of pathological conditions. Tumor growth and metastasis is dependent on the development of new blood vessels. The development of new blood vessels in the eye, or ocular neovascularization, has been implicated in a variety of serious ocular diseases. For instance, choroidal neovascularization is linked to age-related macular degeneration, while retinal neovascularization is linked to diabetic retinopathy. The present invention is based on the discovery of a peptide sequence, C16Y, which inhibits ocular neovascularization and tumor growth in vivo. C16Y is a scrambled version of the C16 peptide sequence from the y1 chain of laminin-1. Unlike C16, which is an angiogenic stimulator, C16Y has been shown to inhibit angiogenesis. The present invention discloses methods of treating ocular neovascularization and cancer using both full-length and truncated versions of the C16Y.
公开/授权文献
信息查询
IPC分类:
